Related Experiment Video
Updated: Aug 1, 2025
Author Spotlight: Advancements in Multiplex Detection of Respiratory Viruses
Published on: November 10, 2023
Assessing and Reassessing the Association of Comorbidities and Coinfections in COVID-19 Patients
Aryaan Khan1, Ahmed El Hosseiny2, Rania Siam3
1Medicine, University of Medicine and Health Sciences, Basseterre, KNA.
Insights
Coinfections like Staphylococcus aureus and comorbidities such as hypertension are common in COVID-19 patients. Understanding these associations aids in managing COVID-19 and its complications.
Area of Science:
- Infectious Diseases
- Epidemiology
- Public Health
Background:
- Coronavirus disease 2019 (COVID-19) presents a significant global health and economic challenge, with millions of cases and deaths reported worldwide.
- Comorbidities and coinfections are frequently observed in patients with severe COVID-19, influencing disease progression and outcomes.
Purpose of the Study:
- To investigate the prevalence of various comorbidities and coinfections in a large cohort of COVID-19 patients.
- To analyze the association between specific comorbidities and coinfections in COVID-19 patients.
- To compare comorbidity patterns in COVID-19 coinfections versus non-COVID-19 coinfections.
Main Methods:
- A comprehensive assessment of data from retrospective, prospective, case series, and case reports.
- Inclusion of approximately 2300 COVID-19 patients with diverse comorbidities and coinfections.
- Statistical analysis to determine significant differences in comorbidity prevalence based on coinfection status and geographical region.
Main Results:
- Enterobacterales with Staphylococcus aureus was the most prevalent coinfection, while Mycoplasma pneumoniae was the least prevalent in COVID-19 patients with comorbidities.
- Hypertension, diabetes, cardiovascular disease, and pulmonary disease were the most common comorbidities observed.
- A statistically significant difference in prevalent comorbidities was noted in patients coinfected with Staphylococcus aureus and COVID-19 compared to non-COVID-19 infections.
Conclusions:
- The study highlights significant variations in comorbidity prevalence among COVID-19 patients with different coinfections and across various geographical regions.
- Findings provide crucial data for evidence-based patient management and care strategies for COVID-19.
- Understanding coinfection and comorbidity patterns is essential for optimizing treatment protocols and improving patient outcomes in the context of COVID-19.
Abstract:
Coronavirus disease 2019 (COVID-19) has posed an enormous global health and economic burden. To date, 324 million confirmed cases and over 5.5 million deaths have been reported. Several studies have reported comorbidities and coinfections associated with complicated and serious COVID-19 infections. Data from retrospective, prospective, case series, and case reports from various geographical locations were assessed, which included ~ 2300 COVID-19 patients with varying comorbidities and coinfection. We report that Enterobacterales with Staphylococcus aureus was the most while Mycoplasma pneumoniae was the least prevalent coinfection in COVID-19 patients with a comorbidity. In this order, hypertension, diabetes, cardiovascular disease, and pulmonary disease were the prevalent comorbidities observed in COVID-19 patients. There was a statistically significant difference in the prevalent comorbidities observed in patients coinfected with Staphylococcus aureus and COVID-19 and a statistically non-significant difference in the prevalent comorbidities in patients coinfected with Mycoplasma pneumoniae and COVID-19 as compared to similar infections in non-COVID-19 coinfection. We report a significant difference in the prevalent comorbidities recorded in COVID-19 patients with varying coinfections and varying geographic study regions. Our study provides informative data on the prevalence of comorbidities and coinfections in COVID-19 patients to aid in evidence-based patient management and care.
Related Concept Videos
01:30Pneumonia III: Complications and Assessment
01:20COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
01:25Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
01:26Factors Affecting the Risk of Infection
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
01:26Healthcare Associated Infections I: Iatrogenic, Exogenic and Endogenic
HAIs significantly increase the cost of health care. Extended stays in healthcare institutions, increased disability, increased costs of medications, including specialized antibiotics, and prolonged recovery times add to the patient's expenses and the healthcare institution and funding bodies.
01:18Factors Affecting Illness
For instance, risk factors are connected to illness,...